Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.

Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, Sagert JG, Hostetter DR, Han F, Gee J, Flandez J, Markham K, Nguyen M, Krimm M, Wong KR, Liu S, Daugherty PS, West JW, Lowman HB.

Sci Transl Med. 2013 Oct 16;5(207):207ra144. doi: 10.1126/scitranslmed.3006682.

2.

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.

French DM, Lin BC, Wang M, Adams C, Shek T, Hötzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K, Rodriguez LA, Hristopoulos M, Venook R, Ashkenazi A, Desnoyers LR.

PLoS One. 2012;7(5):e36713. doi: 10.1371/journal.pone.0036713. Epub 2012 May 15.

3.

FGF19 and cancer.

Lin BC, Desnoyers LR.

Adv Exp Med Biol. 2012;728:183-94. doi: 10.1007/978-1-4614-0887-1_12. Review.

PMID:
22396170
4.

Liver-specific activities of FGF19 require Klotho beta.

Lin BC, Wang M, Blackmore C, Desnoyers LR.

J Biol Chem. 2007 Sep 14;282(37):27277-84. Epub 2007 Jul 11.

5.

Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.

Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM.

Oncogene. 2008 Jan 3;27(1):85-97. Epub 2007 Jun 25.

PMID:
17599042

Supplemental Content

Loading ...
Support Center